Related Experiment Videos
Diabetic retinopathy: surrogate outcomes for drug development for diabetic retinopathy
1Department of Ophthalmology, University Hospital and Center of Ophthalmology, AIBILI and Institute of Biomedical Research on Light and Image, University of Coimbra, Portugal. cunhavaz@imagem.ibili.uc.pt
Abstract:
Diabetic retinopathy remains the most frequent cause of new cases of blindness among adults aged 20-74 years. A number of large clinical trials have validated treatment methods now considered standard. However, the disease continues to progress in approximately 50% of the eyes treated by photocoagulation. Other forms of therapy targeted at the earliest stages of retinal disease are needed. The difficulties in defining and accepting surrogate outcomes appropriate to evaluate the earlier stages of retinopathy are discussed. Special attention is given to trial design and the most likely possibilities for surrogate outcomes: mean difference on the Early Treatment Diabetic Retinopathy Study retinopathy scale of at least 2 steps per eye, reduction in macular thickening and reduction in fluorescein leakage.
Insights
Diabetic retinopathy causes significant blindness, and current treatments are insufficient for half of patients. New therapies targeting early-stage diabetic retinopathy are crucial, requiring validated surrogate outcomes for clinical trials.
Area of Science:
- Ophthalmology
- Diabetology
- Clinical Trials
Background:
- Diabetic retinopathy is a leading cause of adult blindness.
- Established treatments like photocoagulation fail to halt disease progression in about 50% of cases.
- There is a critical need for novel therapeutic strategies targeting earlier stages of the disease.
Purpose of the Study:
- To discuss the challenges in defining and validating surrogate outcomes for early-stage diabetic retinopathy.
- To explore potential surrogate outcomes for evaluating new treatment efficacy.
- To inform the design of future clinical trials for diabetic retinopathy.
Main Methods:
- Review of existing clinical trial data and methodologies.
- Discussion of statistical considerations for surrogate outcome measures.
- Analysis of potential surrogate endpoints such as the Early Treatment Diabetic Retinopathy Study (ETDRS) scale, macular thickening, and fluorescein leakage.
Main Results:
- Photocoagulation therapy is ineffective in approximately 50% of treated eyes.
- Defining reliable surrogate outcomes for early retinopathy stages presents significant challenges.
- Potential surrogate outcomes include a 2-step ETDRS scale improvement, reduced macular thickening, and decreased fluorescein leakage.
Conclusions:
- Effective treatments for diabetic retinopathy progression are still needed.
- Validated surrogate outcomes are essential for advancing early-stage therapeutic interventions.
- Careful trial design incorporating appropriate surrogate endpoints will facilitate the development of new treatments.